{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T01:37:48Z","timestamp":1782524268392,"version":"3.54.5"},"reference-count":19,"publisher":"Cambridge University Press (CUP)","issue":"8","license":[{"start":{"date-parts":[[2013,6,21]],"date-time":"2013-06-21T00:00:00Z","timestamp":1371772800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Nutr"],"published-print":{"date-parts":[[2013,10,28]]},"abstract":"<jats:p>The soluble fibre (1\u00a0\u2192\u00a03)(1\u00a0\u2192\u00a04)-\u03b2-<jats:sc>d<\/jats:sc>-glucan attenuates postprandial glycaemic responses when administered in solution. This attenuating effect is strengthened when solution viscosity is increased by increasing the \u03b2-glucan dose or molecular weight (MW). The effect of varying solution viscosity by changing solution volume, without changing the \u03b2-glucan dose or MW, on glycaemic responses was determined. A total of fifteen healthy subjects received six 50\u00a0g oral glucose beverages prepared with or without 4\u00a0g of high-MW (HMW, 580\u00a0000\u00a0g\/mol) or low-MW (LMW, 145\u00a0000\u00a0g\/mol) \u03b2-glucan, with a beverage volume of 250 or 600\u00a0ml. Postprandial plasma glucose concentration was measured over 2\u00a0h, and the peak blood glucose rise (PBGR) and the incremental area under the glycaemic response curve (AUC) were calculated. Subjects served as their own controls. The physico-chemical properties of the beverages were measured to examine their relationship with glycaemic response results. The HMW \u03b2-glucan beverage was more viscous and achieved greater reductions in PBGR than the glucose beverage with LMW \u03b2-glucan (<jats:italic>P<\/jats:italic>&lt;\u00a00\u00b705). At the same MW, the 250 and 600\u00a0ml \u03b2-glucan beverages differed in viscosity (&gt;9-fold difference) but not in PBGR (<jats:italic>P<\/jats:italic>&gt;0\u00b705). No differences in AUC were detected among the beverages (<jats:italic>P<\/jats:italic>=\u00a00\u00b7147). The effects of \u03b2-glucan on glycaemic response were altered by changes in beverage viscosity achieved through changes in MW but not in volume. Therefore, \u03b2-glucan dose and MW are the most vital characteristics for optimising the bioactivity of \u03b2-glucan solutions with respect to glycaemic response.<\/jats:p>","DOI":"10.1017\/s000711451300069x","type":"journal-article","created":{"date-parts":[[2013,6,21]],"date-time":"2013-06-21T14:48:54Z","timestamp":1371826134000},"page":"1465-1471","source":"Crossref","is-referenced-by-count":32,"title":["Increasing the viscosity of oat \u03b2-glucan beverages by reducing solution volume does not reduce glycaemic responses"],"prefix":"10.1017","volume":"110","author":[{"given":"Melissa G. Y.","family":"Kwong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M. S.","family":"Wolever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda","family":"Brummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Tosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2013,6,21]]},"reference":[{"key":"S000711451300069X_ref14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.6124.1392"},{"key":"S000711451300069X_ref4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1017\/S0007114500001185","article-title":"Evaluation of role of concentration and molecular weight of oat \u03b2-glucan in determining effect of viscosity on plasma glucose and insulin following an oral glucose load","volume":"84","author":"Wood","year":"2000","journal-title":"Br J Nutr"},{"key":"S000711451300069X_ref3","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/87.3.627"},{"key":"S000711451300069X_ref7","doi-asserted-by":"publisher","DOI":"10.1094\/CCHEM-85-3-0289"},{"key":"S000711451300069X_ref2","unstructured":"Health Canada, Bureau of Nutritional Sciences Food Directorate, Health Products and Food Branch (2010) Summary of Assessment of a Health Claim about Oat Products and Blood Cholesterol Lowering. http:\/\/www.hc-sc.gc.ca\/fn-an\/label-etiquet\/claims-reclam\/assess-evalu\/oat-avoine-eng.php."},{"key":"S000711451300069X_ref5","first-page":"731","article-title":"Effect of dose and modification of viscous properties of oat gum on plasma glucose and insulin following an oral glucose load","volume":"72","author":"Wood","year":"1994","journal-title":"Cereal Chem"},{"key":"S000711451300069X_ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00394-009-0778-3"},{"key":"S000711451300069X_ref15","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.2001.280.6.G1227"},{"key":"S000711451300069X_ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S0271-5317(98)00155-9"},{"key":"S000711451300069X_ref18","first-page":"993","article-title":"Dilution of the 75-g oral glucose tolerance test increases postprandial glycemia: implications for diagnostic criteria","volume":"162","author":"Sievenpiper","year":"2000","journal-title":"Can Med Assoc J"},{"key":"S000711451300069X_ref17","doi-asserted-by":"publisher","DOI":"10.1093\/jn\/130.1.122"},{"key":"S000711451300069X_ref8","doi-asserted-by":"publisher","DOI":"10.1094\/CCHEM.1997.74.4.476"},{"key":"S000711451300069X_ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S0268-005X(03)00105-X"},{"key":"S000711451300069X_ref12","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ejcn.1602561"},{"key":"S000711451300069X_ref10","doi-asserted-by":"publisher","DOI":"10.1094\/CCHEM-85-2-0211"},{"key":"S000711451300069X_ref11","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.19.8.831"},{"key":"S000711451300069X_ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S0271-5317(02)00476-1"},{"key":"S000711451300069X_ref6","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/54.5.846"},{"key":"S000711451300069X_ref1","unstructured":"United States Food and Drug Administration (2010) Code of Federal Regulations, Title 21 \u2013 Food and Drugs, Volume 2, 21CFR101.81."}],"container-title":["British Journal of Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S000711451300069X","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T22:53:00Z","timestamp":1595976780000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S000711451300069X\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,21]]},"references-count":19,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,10,28]]}},"alternative-id":["S000711451300069X"],"URL":"https:\/\/doi.org\/10.1017\/s000711451300069x","relation":{},"ISSN":["0007-1145","1475-2662"],"issn-type":[{"value":"0007-1145","type":"print"},{"value":"1475-2662","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,21]]}}}